Biotech
Grail
Grail raises $390M Series D at $6.3B valuation
$390M
Total Raised
Series D
Latest Round
2016
Founded
500+
Employees
Menlo Park, CA
1 min read
Quick Facts
Valuation
$6.3B
Latest Round Size
$390M
Latest Round Date
May 2020
Grail: Series D Funding Round
Grail has successfully raised $390M in Series D funding, reaching a valuation of $6.3B.
Company Overview
Multi-cancer early detection blood test
Funding Details
The Series D round was led by ARCH Venture Partners, with participation from Johnson & Johnson.
Company Information
- Headquarters: Menlo Park, CA
- Founded: 2016
- Employees: 500+
- Category: Biotech
Investment
Grail plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- ARCH Venture Partners: Verified investor in Series D
- Johnson & Johnson: Verified investor in Series D
Key Investors
ARCH Venture Partners
Lead Investor
Verified investor in Series D
Johnson & Johnson
Investor
Verified investor in Series D
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M